Plain-English translation of NCT07223723 on ClinicalTrials.gov ↗ ·
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a new medication designed to slow the progression of a genetic form of ALS caused by changes in the SOD1 gene. The study will track how safe and well-tolerated this medication is when given as injections into the spinal fluid over about a year. Researchers want to learn more about how this treatment works in Chinese patients with this specific type of ALS.
SOD1-related ALS is a rare genetic form of this disease, and patients have very limited treatment options. This medication was designed specifically to target the genetic cause of this type of ALS, and this study will help doctors understand how safe and effective the treatment is in real-world use.
You likely qualify if…
You likely don't qualify if…
You would receive a series of injections of the medication directly into your spinal fluid over about 11 months. The first three injections happen every 2 weeks, then you would receive maintenance injections every 4 weeks for a total of 13 doses. Throughout the study, you would have visits where doctors check your safety, take blood samples, and monitor how your body is responding to the treatment.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China